is tirzepatide still in shortage The recent announcement that has been removed from the FDA's drug list good news for people looking for effective weight loss solutions. But, it could mean the compounded versions tirzepatide off the shortage list

It is not yet licensed by the MHRA or EMA

159 As of now, GLP-1-related triple agonists are primarily still in the development stage and have not been widely approved for use

Improper self-medi cation increases risks like: Too much semaglutide can cause severe nausea, vomiting, and dangerously low blood sugar

submission for type 2 diabetes was planned for later in 2026

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (familiar brand names include Jardiance, Farxiga, Ozempic, Wegovy, Mounjaro, Zepbound, Victoza ) are increasingly popular options, not only for glycemic control among patients with diabetes, but also for heart failure management and weight losseven in non-diabetics